INVESTORS

ONENESS & MICROBIO (Shanghai) International Press Conference
SNS812 Pan-COVID New Drug Phase 2 (SNS812CLCT02) Results

SNS812, a Pan-COVID new drug, co-developed by ONENESS & MICROBIO (Shanghai) has completed the Phase 2 double-blind, placebo-controlled study. The international press conference will be hosted by Oneness Biotech and Microbio (Shanghai) and joined by Pan-Chyr Yang M.D., Ph.D., the Academia Sinica Academician & Chief Scientific Advisor of Oneness, Prof. Shey-Ying Chen, M.D., Ph.D., the lead principal investigator of SNS812 Phase 2 study and the Department of Emergency Medicine at NTU, Prof. Sui-Yuan Chang, Ph.D., the virologist and Department of Clinical Laboratory Science and Medical Biotechnology at NTU. The unblinded Phase 2 study results and the subsequent plan of SNS812 will be presented. We sincerely invite all media friends to attend.

Distinguished Guests

• Pan-Chyr Yang, M.D., Ph.D.,
  The Academia Sinica Academician & Chief Scientific Advisor of Oneness
• Prof. Sui-Yuan Chang, Ph.D.,
  The virologist and Department of Clinical Laboratory Science and Medical Biotechnology at NTU
• Prof. Shey-Ying Chen, M.D., Ph.D.,
  The lead principal pnvestigator of SNS812 Phase 2 study and the Department of Emergency Medicine at NTU

Organizers

• Shuling Cheng, PhD., President of Oneness Biotech
• Yi-Chung Chang, PhD., President of Microbio (Shanghai)

▍Date: Monday, September 9th, 2024

▍Time: 3:30 PM - 5:00 PM (Media check-in begins at 3:00 PM)

▍Location: Grand Hyatt Taipei, 3F, Hyatt Hall

▍Media Contact: 陳雅言 Cathy Chen 0935200874, cathy.chen@how-living.com

We will be hosting a simultaneous online press conference. Media friends, investors, and interested parties who are unable to attend in person are welcome to join us online to stay updated on the latest information.